Join the club for FREE to access the whole archive and other member benefits.

Magnitude Biosciences

Biotechnology company that combines experience in ageing research, the nematode C. elegans and automation

We are a specialist Contract Research Organisation (CRO) who help industry and academia progress their research projects via our team of expert scientists, C. elegans services and unique automated imaging technology. Our C. elegans studies are customised to answer your key research questions and generate high-quality, reproducible data to accelerate your research project to the next stage. 

We were founded in 2018 by a team of the world’s leading C. elegans and automated imaging experts who shared the vision of bringing the benefits of this unique research approach to industry, helping to play our part in accelerating the development of new drug therapies and other research advances to improve human and environmental health. Although there are many C. elegans academic labs around the world, there are very few commercial labs that exist to apply the benefits of C. elegans research to the biotechnology and consumer goods industries.

Magnitude Biosciences Executive Team

• Fozia Saleem, CEO

• David Weinkove, CSO

• Chris Saunter, CTO

• Sally Waterman, Non-Executive Director & Chair of the Board

Magnitude Biosciences Advisory Board

• Gordon Lithgow

• Liping Zhao

• Rozalyn Anderson

Visit website:




Mentioned in this Resource

Chris Saunter

Director at Magnitude Biosciences, High speed imaging

David Weinkove

CEO at Magnitude Biosciences and Associate Professor at Durham University

Fozia Saleem

Innovator, Transformative Leadership and CEO at Magnitude Biosciences

Gordon Lithgow

Professor at The Buck Institute

Liping Zhao

Professor of Applied Microbiology at the Rutgers University

Rozalyn Anderson

Associate Professor at University of Wisconsin-Madison.

Sally Waterman

Non-Executive Director & Chair of the Board at Magnitude Biosciences

Magnitude Biosciences News

£500K in 4th round funding to scale-up Magnitude Biosciences' C. elegans research services

Magnitude Biosciences - 14-Nov-2022

Advances in AI is great, but this sort of automation is what will create the data it needs to find new longevity drugs


Five Alarm Bio to develop drug treatment not to cure ageing but improve healthy lifespan

Cambridge Independent - 04-Nov-2022

The company aims at treatments for a range of diseases associated with ageing and disabilities


Ageing-related drug screening made easy and reproducible with automated tech

Longevity Technology - 18-Aug-2022

Camera on each petri dish captures healthspan of many worms simultaneously